How much funding has Nkarta raised?

Nkarta has raised $126.8M in total funding, most recently a Series B round.

Who are Nkarta's investors?

Nkarta's investors include Boxer Capital, Samsara BioCapital, Amgen, RA Capital Management, GlaxoSmithKline.

Where is Nkarta headquartered?

Nkarta is headquartered in South San Francisco, California, United States.

What industry is Nkarta in?

Nkarta operates in Biotech, Healthcare.

Nkarta

IPO

Pioneering off-the-shelf NK cell therapy for autoimmune disease

Public · South San Francisco, United States · Founded 2015 · $126.8M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2015
Business Model: B2B
Website: nkarta.com

Total Funding: $126.8M
Last Round: $114.0M Series BSep 2019
Rounds: 2
Type: Public

About

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies to treat autoimmune disease. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of NK cell therapies engineered for deep therapeutic impact. The company's lead candidate, NKX019, targets CD19-expressing B cells and is designed to be administered in outpatient settings without the manufacturing complexity or safety risks of autologous CAR-T therapies.

Summary

Nkarta is a Biotech company based in South San Francisco, United States, founded in 2015. It has raised $126.8M in total across 2 rounds, most recently a $114.0M Series B round in Sep 2019. Investors include Boxer Capital, Samsara BioCapital and Amgen.